[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
Affiliations: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang university, Hangzhou, Zhejiang 310003, P.R. China, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang university School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, Guangdong 518103, P.R. China
- Published online on: September 19, 2022 https://doi.org/10.3892/or.2022.8411
- Article Number: 196
Copyright : © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Rep 37: [Related article:] 2215–2226, 2017; DOI: 10.3892/or.2017.5494
Subsequently to the publication of the above article, the authors have realized that a couple of clerical errors were made when writing the article, and wish to correct these errors in a corrigendum statement. First, in the Materials and methods section on p. 2216, the final sentence of the ‘Immunohistochemistry and tissue microarray’ subsection, the authors wish to add a further definition, so that the text reads as follows (changes highlighted in bold): ‘The positive expression of RET was defined as ≥5% staining of a tumor section; high expression was defined as ≥40% staining of a tumor section, and low expression as <40%’. Secondly, in the Results section, ‘Mutation frequency of each gene distributed in 4 biological categories’ subsection, p. 2220, right-hand column, second paragraph, line 17, the sentence written here should have read as follows: ‘The group with the positive expression of RET included 28.9% (26/90) of the patients, and 4 of these patients were defined as high expression’.
The authors are grateful to the Editor of Oncology Reports for allowing them this opportunity to publish a corrigendum, and apologize to the readership of the journal for any inconvenience caused.